CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Retained Earnings
Balance at Dec. 31, 2021	$ 1,750,067,000	$ 553,000	$ 1,572,340,000	$ (16,886,000)	$ 194,060,000
Beginning Balance (in shares) at Dec. 31, 2021		55,321,457
Net income	137,230,000				137,230,000
Issuance of common stock for debt conversion	(5,000)	$ 0	(5,000)
Issuance of common stock for debt conversion (in shares)		15
Exercise of stock options and vesting of stock units	2,784,000	$ 3,000	2,781,000
Exercise of stock options and vesting of stock units (in shares)		281,839
Tax withholding on vesting of restricted stock units	(15,829,000)	$ (1,000)	(15,828,000)
Tax withholding on vesting of restricted stock units (in shares)		(83,665)
Stock-based compensation expense	21,054,000		21,054,000
Translation adjustment	(38,375,000)			(38,375,000)
Balance at Sep. 30, 2022	1,835,109,000	$ 555,000	1,541,272,000	(55,261,000)	348,543,000
Balance (Accounting Standards Update 2020-06 [Member]) at Sep. 30, 2022	(21,817,000)		(39,070,000)		17,253,000
Ending Balance (in shares) at Sep. 30, 2022		55,519,646
Balance at Jun. 30, 2022	1,805,364,000	$ 555,000	1,533,762,000	(37,091,000)	308,138,000
Beginning Balance (in shares) at Jun. 30, 2022		55,465,918
Net income	40,405,000				40,405,000
Issuance of common stock for debt conversion	0	$ 0	0
Issuance of common stock for debt conversion (in shares)		3
Exercise of stock options and vesting of stock units	2,321,000	$ 0	2,321,000
Exercise of stock options and vesting of stock units (in shares)		59,112
Tax withholding on vesting of restricted stock units	(1,070,000)	$ 0	(1,070,000)
Tax withholding on vesting of restricted stock units (in shares)		(5,387)
Stock-based compensation expense	6,154,000		6,154,000
Translation adjustment	(18,170,000)			(18,170,000)
Other	105,000		105,000
Balance at Sep. 30, 2022	1,835,109,000	$ 555,000	1,541,272,000	(55,261,000)	348,543,000
Balance (Accounting Standards Update 2020-06 [Member]) at Sep. 30, 2022	(21,817,000)		(39,070,000)		17,253,000
Ending Balance (in shares) at Sep. 30, 2022		55,519,646
Balance at Dec. 31, 2022	1,910,700,000	$ 556,000	1,547,266,000	(34,394,000)	397,272,000
Beginning Balance (in shares) at Dec. 31, 2022		55,557,698
Net income	52,046,000				52,046,000
Issuance of common stock for debt conversion	(13,000)		(13,000)
Issuance of common stock for debt conversion (in shares)		8
Exercise of stock options and vesting of stock units	356,000	$ 3,000	353,000
Exercise of stock options and vesting of stock units (in shares)		212,589
Tax withholding on vesting of restricted stock units	(12,178,000)	$ (1,000)	(12,177,000)
Tax withholding on vesting of restricted stock units (in shares)		(69,625)
Issuance of commons stock pursuant to the acquisition	5,465,000		5,465,000
Issuance of commons stock pursuant to the acquisition, (in shares)		31,415
Issuance of common stock pursuant to the acquisition of FlexBiosys, Inc.	7,229,000		7,229,000
Issuance of common stock pursuant to the Avitide, Inc.contingent consideration earnout payment		$ 42,621
Stock-based compensation expense	19,110,000		19,110,000
Translation adjustment	(8,972,000)			(8,972,000)
Balance at Sep. 30, 2023	1,973,743,000	$ 558,000	1,567,233,000	(43,366,000)	449,318,000
Ending Balance (in shares) at Sep. 30, 2023		55,774,706
Balance at Jun. 30, 2023	1,956,859,000	$ 557,000	1,561,393,000	(37,486,000)	432,395,000
Beginning Balance (in shares) at Jun. 30, 2023		55,744,896
Net income	16,923,000				16,923,000
Issuance of common stock for debt conversion	(10,000)		(10,000)
Issuance of common stock for debt conversion (in shares)		2
Exercise of stock options and vesting of stock units	294,000	$ 1,000	293,000
Exercise of stock options and vesting of stock units (in shares)		36,195
Tax withholding on vesting of restricted stock units	(1,038,000)		(1,038,000)
Tax withholding on vesting of restricted stock units (in shares)		(6,387)
Issuance of commons stock pursuant to the acquisition	222,000		222,000
Stock-based compensation expense	6,373,000		6,373,000
Translation adjustment	(5,880,000)			(5,880,000)
Balance at Sep. 30, 2023	$ 1,973,743,000	$ 558,000	$ 1,567,233,000	$ (43,366,000)	$ 449,318,000
Ending Balance (in shares) at Sep. 30, 2023		55,774,706